Literature DB >> 26374690

Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter--still a dilemma?

Monika E Hegi1, Roger Stupp1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26374690      PMCID: PMC4648310          DOI: 10.1093/neuonc/nov198

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  14 in total

1.  Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.

Authors:  Annika Malmström; Bjørn Henning Grønberg; Christine Marosi; Roger Stupp; Didier Frappaz; Henrik Schultz; Ufuk Abacioglu; Björn Tavelin; Benoit Lhermitte; Monika E Hegi; Johan Rosell; Roger Henriksson
Journal:  Lancet Oncol       Date:  2012-08-08       Impact factor: 41.316

2.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.

Authors:  M Esteller; J Garcia-Foncillas; E Andion; S N Goodman; O F Hidalgo; V Vanaclocha; S B Baylin; J G Herman
Journal:  N Engl J Med       Date:  2000-11-09       Impact factor: 91.245

3.  Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.

Authors:  L Burt Nabors; Karen L Fink; Tom Mikkelsen; Danica Grujicic; Rafal Tarnawski; Do Hyun Nam; Maria Mazurkiewicz; Michael Salacz; Lynn Ashby; Vittorina Zagonel; Roberta Depenni; James R Perry; Christine Hicking; Martin Picard; Monika E Hegi; Benoit Lhermitte; David A Reardon
Journal:  Neuro Oncol       Date:  2015-03-11       Impact factor: 12.300

4.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.

Authors:  Olivier L Chinot; Wolfgang Wick; Warren Mason; Roger Henriksson; Frank Saran; Ryo Nishikawa; Antoine F Carpentier; Khe Hoang-Xuan; Petr Kavan; Dana Cernea; Alba A Brandes; Magalie Hilton; Lauren Abrey; Timothy Cloughesy
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

5.  A randomized trial of bevacizumab for newly diagnosed glioblastoma.

Authors:  Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

6.  Transforming fusions of FGFR and TACC genes in human glioblastoma.

Authors:  Devendra Singh; Joseph Minhow Chan; Pietro Zoppoli; Francesco Niola; Ryan Sullivan; Angelica Castano; Eric Minwei Liu; Jonathan Reichel; Paola Porrati; Serena Pellegatta; Kunlong Qiu; Zhibo Gao; Michele Ceccarelli; Riccardo Riccardi; Daniel J Brat; Abhijit Guha; Ken Aldape; John G Golfinos; David Zagzag; Tom Mikkelsen; Gaetano Finocchiaro; Anna Lasorella; Raul Rabadan; Antonio Iavarone
Journal:  Science       Date:  2012-07-26       Impact factor: 47.728

7.  Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.

Authors:  Mark R Gilbert; Meihua Wang; Kenneth D Aldape; Roger Stupp; Monika E Hegi; Kurt A Jaeckle; Terri S Armstrong; Jeffrey S Wefel; Minhee Won; Deborah T Blumenthal; Anita Mahajan; Christopher J Schultz; Sara Erridge; Brigitta Baumert; Kristen I Hopkins; Tzahala Tzuk-Shina; Paul D Brown; Arnab Chakravarti; Walter J Curran; Minesh P Mehta
Journal:  J Clin Oncol       Date:  2013-10-07       Impact factor: 44.544

8.  Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.

Authors:  Roger Stupp; Monika E Hegi; Thierry Gorlia; Sara C Erridge; James Perry; Yong-Kil Hong; Kenneth D Aldape; Benoit Lhermitte; Torsten Pietsch; Danica Grujicic; Joachim Peter Steinbach; Wolfgang Wick; Rafał Tarnawski; Do-Hyun Nam; Peter Hau; Astrid Weyerbrock; Martin J B Taphoorn; Chiung-Chyi Shen; Nalini Rao; László Thurzo; Ulrich Herrlinger; Tejpal Gupta; Rolf-Dieter Kortmann; Krystyna Adamska; Catherine McBain; Alba A Brandes; Joerg Christian Tonn; Oliver Schnell; Thomas Wiegel; Chae-Yong Kim; Louis Burt Nabors; David A Reardon; Martin J van den Bent; Christine Hicking; Andriy Markivskyy; Martin Picard; Michael Weller
Journal:  Lancet Oncol       Date:  2014-08-19       Impact factor: 41.316

Review 9.  MGMT testing--the challenges for biomarker-based glioma treatment.

Authors:  Wolfgang Wick; Michael Weller; Martin van den Bent; Marc Sanson; Markus Weiler; Andreas von Deimling; Christoph Plass; Monika Hegi; Michael Platten; Guido Reifenberger
Journal:  Nat Rev Neurol       Date:  2014-06-10       Impact factor: 42.937

10.  Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.

Authors:  Wolfgang Wick; Michael Platten; Christoph Meisner; Jörg Felsberg; Ghazaleh Tabatabai; Matthias Simon; Guido Nikkhah; Kirsten Papsdorf; Joachim P Steinbach; Michael Sabel; Stephanie E Combs; Jan Vesper; Christian Braun; Jürgen Meixensberger; Ralf Ketter; Regine Mayer-Steinacker; Guido Reifenberger; Michael Weller
Journal:  Lancet Oncol       Date:  2012-05-10       Impact factor: 41.316

View more
  34 in total

1.  MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials.

Authors:  Monika E Hegi; Els Genbrugge; Thierry Gorlia; Roger Stupp; Mark R Gilbert; Olivier L Chinot; L Burt Nabors; Greg Jones; Wim Van Criekinge; Josef Straub; Michael Weller
Journal:  Clin Cancer Res       Date:  2018-12-04       Impact factor: 12.531

Review 2.  Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.

Authors:  Patrick Y Wen; Michael Weller; Eudocia Quant Lee; Brian M Alexander; Jill S Barnholtz-Sloan; Floris P Barthel; Tracy T Batchelor; Ranjit S Bindra; Susan M Chang; E Antonio Chiocca; Timothy F Cloughesy; John F DeGroot; Evanthia Galanis; Mark R Gilbert; Monika E Hegi; Craig Horbinski; Raymond Y Huang; Andrew B Lassman; Emilie Le Rhun; Michael Lim; Minesh P Mehta; Ingo K Mellinghoff; Giuseppe Minniti; David Nathanson; Michael Platten; Matthias Preusser; Patrick Roth; Marc Sanson; David Schiff; Susan C Short; Martin J B Taphoorn; Joerg-Christian Tonn; Jonathan Tsang; Roel G W Verhaak; Andreas von Deimling; Wolfgang Wick; Gelareh Zadeh; David A Reardon; Kenneth D Aldape; Martin J van den Bent
Journal:  Neuro Oncol       Date:  2020-08-17       Impact factor: 12.300

3.  NovoTTF: where to go from here?

Authors:  Timothy F Cloughesy; Andrew B Lassman
Journal:  Neuro Oncol       Date:  2017-05-01       Impact factor: 12.300

4.  Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort study.

Authors:  H Pinson; G Hallaert; J Van der Meulen; F Dedeurwaerdere; D Vanhauwaert; C Van den Broecke; J Van Dorpe; D Van Roost; J P Kalala; T Boterberg
Journal:  J Neurooncol       Date:  2019-11-07       Impact factor: 4.130

5.  The clinical trials landscape for glioblastoma: is it adequate to develop new treatments?

Authors:  Alyssa M Vanderbeek; Rifaquat Rahman; Geoffrey Fell; Steffen Ventz; Tianqi Chen; Robert Redd; Giovanni Parmigiani; Timothy F Cloughesy; Patrick Y Wen; Lorenzo Trippa; Brian M Alexander
Journal:  Neuro Oncol       Date:  2018-07-05       Impact factor: 12.300

6.  The effects of tumor treating fields and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells.

Authors:  Paul A Clark; Jordan T Gaal; Joslyn K Strebe; Cheri A Pasch; Dustin A Deming; John S Kuo; H Ian Robins
Journal:  J Clin Neurosci       Date:  2016-11-16       Impact factor: 1.961

Review 7.  The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients.

Authors:  Craig Horbinski; Keith L Ligon; Priscilla Brastianos; Jason T Huse; Monica Venere; Susan Chang; Jan Buckner; Timothy Cloughesy; Robert B Jenkins; Caterina Giannini; Roger Stupp; L Burt Nabors; Patrick Y Wen; Kenneth J Aldape; Rimas V Lukas; Evanthia Galanis; Charles G Eberhart; Daniel J Brat; Jann N Sarkaria
Journal:  Neuro Oncol       Date:  2019-12-17       Impact factor: 12.300

Review 8.  The evolving role for re-irradiation in the management of recurrent grade 4 glioma.

Authors:  Steven P Howard; Andra Krauze; Mike D Chan; Christina Tsien; Wolfgang A Tomé
Journal:  J Neurooncol       Date:  2017-04-06       Impact factor: 4.130

Review 9.  Recent Advances on the Molecular Pathology of Glial Neoplasms in Children and Adults.

Authors:  Fausto J Rodriguez; M Adelita Vizcaino; Ming-Tseh Lin
Journal:  J Mol Diagn       Date:  2016-09       Impact factor: 5.568

10.  MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges.

Authors:  Alireza Mansouri; Laureen D Hachem; Sheila Mansouri; Farshad Nassiri; Normand J Laperriere; Daniel Xia; Neal I Lindeman; Patrick Y Wen; Arnab Chakravarti; Minesh P Mehta; Monika E Hegi; Roger Stupp; Kenneth D Aldape; Gelareh Zadeh
Journal:  Neuro Oncol       Date:  2019-02-14       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.